-
Because it had been publicized as being effective for all types of MG, including seronegative, my neurologist and I had been looking forward to Vyvgart’s FDA approval. I am seronegative, and although I am currently taking prednisone, methotrexate, Mestinon, and Plex every two weeks, I am still symptomatic when the Plex wears off. We had hoped that, at the very least, Vyvgart would have freed me from having to have regular Plex treatments. Now it looks as if I will be taking more methotrexate or perhaps try yet another immunosuppressant (methotrexate is my 3rd besides prednisone), and since my antecubital veins are balking, I will probably have to have a port installed. Since I am running out of options, I would have been thrilled to take a drug that is new on the market.
For a couple weeks, I was upset about Vyvgart not being FDA approved for SN MG. But thanks to the kindness of MG patients who have posted on support sites like this one, I have reconciled myself to the idea of having a port.
Vyvgart apparently has a different molecular target from previous MG treatments. I am looking forward to (wistfully) hearing how patients do on it.